# CV - Michael Frühwald

**Personal data**

| | |
|---|---|
| Name and academic title: | Professor Dr. Dr. Michael C. Frühwald |
| Date of birth: | February 24th, 1966 |
| Institution: | Paediatric and Adolescent Medicine<br>University Medical Center Augsburg, University of Augsburg |
| Address: | Stenglinstr. 2, 86156 Augsburg |
| Email address: | michael.fruehwald@uk-augsburg.de |
| Current position: | Full Professor |

**Academic Education and Degrees**

| | |
|---|---|
| 2004 | Habilitation (Pediatrics), Westfalian-Wilhelms-University Münster<br>*Thesis: "Epigenetische und genetische Charakterisierungsmerkmale von Medulloblastomen und sPNET des ZNS im Kindesalter"* |
| 1999 | PhD (Neurosciences), The Ohio State University, Columbus Ohio, USA<br>*Thesis: "Medulloblastoma: A developmental abnormality of the cerebellum"* |
| 1995 | Dr. med. (Medicine): *"Surfactanttherapie bei Frühgeborenen: Vergleich von zwei Päparationen aus Rinderlungen",* Julius-Maximimilians-University Würzburg |

**Professional Experience**

| | |
|---|---|
| Since 2020 | Full Professor of Paediatrics and Adolescent Medicine, University of Augsburg |
| 2008–2020 | Associate Professor, Westfalian-Wilhelms-University Münster |
| Since 2010 | Director Paediatric and Adolescent Medicine, University Medical Center Augsburg |
| Since 2013 | Spokesman of the Clinical Ethics Committee, University Medical Center Augsburg |
| 2006–2010 | Chief Attending, Department of Pediatric Haematology and Oncology, Westfalian-Wilhelms-University Münster |
| 2004–2006 | Resident, Pediatrics, University Hospital Münster |
| 1996–1999/ 2000–2004 | Resident in Pediatrics, University Medical Center, Würzburg and University Hospital, Münster |
| 1996–1999 | Postdoc and Graduate Student (Dr. Mildred Scheel Foundation for Cancer ResearchDeutsche Krebshilfe), The Ohio State University (Columbus/Ohio, USA), (Division of Human Cancer Genetics, Department of Neuroscience) and Children's Hospital (Columbus/Ohio, USA) |

**Publications** (208 articles published in peer-reviewed jounals, 28 book chapters, H-Index=35)

(1) Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population. Nemes K, Johann PD, Steinbügl M, Gruhle M, Bens S, Kachanov D, Teleshova M, Hauser P, Simon T, Tippelt S, Eberl W, Chada M, Lopez VS, Grigull L, Hernáiz-Driever P, Eyrich M, Pears J, Milde T, Reinhard H, Leipold A, van de Wetering M, Gil-da-Costa MJ, Ebetsberger-Dachs G, Kerl K, Lemmer A, Boztug H, Furtwängler R, Kordes U, Vokuhl C, Hasselblatt M, Bison B, Kröncke T, Melchior P, Timmermann B, Gerss J, Siebert R, **Frühwald MC. Cancers** (Basel). 2022 Apr 27;14(9):21

(2) ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance. Federico A, Thomas C, Miskiewicz K, Woltering N, Zin F, Nemes K, Bison B, Johann PD, Hawes D, Bens S, Kordes U, Albrecht S, Dohmen H, Hauser P, Keyvani K, van Landeghem FKH, Lund EL, Scheie D, Mawrin C, Monoranu CM, Parm Ulhøi B, Pietsch T, Reinhard H, Riemenschneider MJ, Sehested A, Sumerauer D, Siebert R, Paulus W, **Frühwald MC**, Kool M, Hasselblatt M. **Acta Neuropathol**. 2022 Jun;143(6):697-711. doi: 10.1007/s00401-022-02424-5 (shared senior authors)

(3) SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. Hasselblatt M, Thomas C, Federico A, Nemes K, Johann PD, Bison B, Bens S, Dahlum S, Kordes U, Redlich A, Lessel L, Pajtler KW, Mawrin C, Schüller U, Nolte K, Kramm CM, Hinz F, Sahm F, Giannini C, Penkert J, Kratz CP, Pfister SM, Siebert R, Paulus W, Kool M, **Frühwald MC**. Am J Surg Pathol. 2022 Sep 1;46(9):1277-1283. doi: 10.1097/PAS.0000000000001905

(4) Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Steinbügl M, Nemes K, Johann P, Kröncke T, Tüchert S, da Costa MJG, Ebinger M, Schüller U, Sehested A, Hauser P, Reinhard H, Sumerauer D, Hettmer S, Jakob M, Hasselblatt M, Siebert R, Witt O, Gerss J, Kerl K, **Frühwald MC. Pediatr Blood Cancer**. 2021 Dec;68(12):e29267. doi: 10.1002/pbc.29267

(5) Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. **Frühwald MC**, Nemes K, Boztug H, Cornips MCA, Evans DG, Farah R, Glentis S, Jorgensen M, Katsibardi K, Hirsch S, Jahnukainen K, Kventsel I, Kerl K, Kratz CP, Pajtler KW, Kordes U, Ridola V, Stutz E, Bourdeaut F. **Fam Cancer**. 2021 Feb 3. doi: 10.1007/s10689-021-00229-1

(6) Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). Nemes K, Bens S, Kachanov D, Teleshova M, Hauser P, Simon T, Tippelt S, Woessmann W, Beck O, Flotho C, Grigull L, Driever PH, Schlegel PG, Khurana C, Hering K, Kolb R, Leipold A, Abbink F, Gil-Da-Costa MJ, Benesch M, Kerl K, Lowis S, Marques CH, Graf N, Nysom K, Vokuhl C, Melchior P, Kröncke T, Schneppenheim R, Kordes U, Gerss J, Siebert R, Furtwängler R, **Frühwald MC. Eur J Cancer. 2021** Jan;142:112-122

(7) Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, Xu P, Mueller S, Yecies DW, Finetti MA, Williamson D, Johann PD, Kool M, Pfister S, Hasselblatt M, **Frühwald MC**, Delattre O, Surdez D, Bourdeaut F, Puget S, Zaidi S, Mitra SS, Cheshier S, Sorensen PH, Monje M, Mackall CL. **Nat Med.** 2020 May;26(5):712-719.

(8) **Frühwald, M.C.**, Hasselblatt, M., Nemes, K., Bens, S., Steinbügl, M., Johann, P.D., Kerl, K., Hauser, P., Quiroga, E., Solano-Paez, P., Biassoni, V., Gil-da-Costa, M.J., Perek-Polnik, M., van de Wetering, M., Sumerauer, D., Pears, J., Stabell, N., Holm, S., Hengartner, H., Gerber, N.U., Grotzer, M., Boos, J., Ebinger, M., Tippelt, S., Paulus, W., Furtwängler, R., Hernáiz-Driever, P., Reinhard, H., Rutkowski, S., Schlegel, P.G., Schmid, I., Kortmann, R.D., Timmermann, B., Warmuth-Metz, M., Kordes, U., Gerss, J., Nysom, K., Schneppenheim, R., Siebert, R., Kool, M., Graf, N. (2020). Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. **Neuro Oncology**, 22(7), 1006-1017.

## Grants / Awards /Skills

M.C. Frühwald, has received several grants from the German Research Foundation (e.g. DFG FR1516/4-1), the DKH (Deutsche Krebshilfe, 70113981) and other German funding agencies (e.g. DKS 2020.10). Alltogether awarded grants sum up to approx. 3.3 Mill. €

MCF received the 20th Annual Research Forum Award of the Children's Research Institute, Columbus, Ohio, USA (1999). Furthermore, he received fellowships from the DKH (1996-1999), the Kind-Philipp-Stiftung (1999-2001) and the Neuroscience program of The Ohio State University (1998-1999).

His methodological skills encompass genetic and epigenetic analyses of tumors, clinical trial design and performance and the ethical counselling of medical teams and pateints as well as their advocates.